Loading…
Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure
Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) ra...
Saved in:
Published in: | American journal of hypertension 2012-06, Vol.25 (6), p.690-696 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3 |
container_end_page | 696 |
container_issue | 6 |
container_start_page | 690 |
container_title | American journal of hypertension |
container_volume | 25 |
creator | Haller, Steven T. Kennedy, David J. Shidyak, Amjad Budny, George V. Malhotra, Deepak Fedorova, Olga V. Shapiro, Joseph I. Bagrov, Alexei Y. |
description | Background
Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats.
Methods
In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery.
Results
In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced.
Conclusions
In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy. |
doi_str_mv | 10.1038/ajh.2012.17 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3355226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1038/ajh.2012.17</oup_id><sourcerecordid>1015094089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</originalsourceid><addsrcrecordid>eNp9kc1r3DAQxUVpaLZpT70XQ2koFG81smzZl0IJ_Qik9NKexUiW1lq80layU_LfR85u049D0GEE8-PNvHmEvAC6Blq173A7rBkFtgbxiKyg41AKxurHZEXbri4FbeCUPE1pSynlTQNPyCljlWhpVa3I8DX4oMfgcSzQT06F_qbADTqfpmKH0fmgZosb450vork2MZlUaIy9Q11Yp2JILhVLE6dU_HLTUOghBu90xhdVi26co3lGTiyOyTw_1jPy49PH7xdfyqtvny8vPlyVmgs6lW3bWKY050YDFUzUive1bVibP5AfV0II2vYtUFSgVcMa3fTMql4w4DVWZ-T9QXc_q53ptfFTxFHuo8tubmRAJ__teDfITbiWVVXXjDVZ4M1RIIafs0mT3LmkzTiiN2FOEijUtOP5thl99R-6DXPMpu-oqmsZCMjU2wOl861SNPZ-GaBySVDmBOWSoASR6Zd_73_P_o4sA6-PACaNo43otUt_uLoT2cfCnR-4MO8fnHgL_VmxSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013982171</pqid></control><display><type>article</type><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</creator><creatorcontrib>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</creatorcontrib><description>Background
Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats.
Methods
In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery.
Results
In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced.
Conclusions
In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>EISSN: 1879-1905</identifier><identifier>DOI: 10.1038/ajh.2012.17</identifier><identifier>PMID: 22378033</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Basingstoke: Oxford University Press</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Bufanolides - immunology ; Bufanolides - metabolism ; Cardiology. Vascular system ; Cardiomegaly - etiology ; Cardiomegaly - metabolism ; Cardiomegaly - prevention & control ; Comorbidity ; Disease Models, Animal ; Experimental diseases ; Fibrosis ; Immunoglobulin Fab Fragments - pharmacology ; Immunoglobulin Fab Fragments - therapeutic use ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - metabolism ; Kidney Failure, Chronic - surgery ; Male ; Medical sciences ; Myocardium - metabolism ; Myocardium - pathology ; Nephrectomy ; Proto-Oncogene Protein c-fli-1 - metabolism ; Rats ; Rats, Sprague-Dawley</subject><ispartof>American journal of hypertension, 2012-06, Vol.25 (6), p.690-696</ispartof><rights>American Journal of Hypertension, Ltd. © 2012 by the American Journal of Hypertension, Ltd. 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jun 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</citedby><cites>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25975223$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22378033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haller, Steven T.</creatorcontrib><creatorcontrib>Kennedy, David J.</creatorcontrib><creatorcontrib>Shidyak, Amjad</creatorcontrib><creatorcontrib>Budny, George V.</creatorcontrib><creatorcontrib>Malhotra, Deepak</creatorcontrib><creatorcontrib>Fedorova, Olga V.</creatorcontrib><creatorcontrib>Shapiro, Joseph I.</creatorcontrib><creatorcontrib>Bagrov, Alexei Y.</creatorcontrib><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><title>American journal of hypertension</title><addtitle>Am J Hypertens</addtitle><description>Background
Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats.
Methods
In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery.
Results
In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced.
Conclusions
In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure - physiology</subject><subject>Bufanolides - immunology</subject><subject>Bufanolides - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomegaly - etiology</subject><subject>Cardiomegaly - metabolism</subject><subject>Cardiomegaly - prevention & control</subject><subject>Comorbidity</subject><subject>Disease Models, Animal</subject><subject>Experimental diseases</subject><subject>Fibrosis</subject><subject>Immunoglobulin Fab Fragments - pharmacology</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Nephrectomy</subject><subject>Proto-Oncogene Protein c-fli-1 - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0895-7061</issn><issn>1941-7225</issn><issn>1879-1905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kc1r3DAQxUVpaLZpT70XQ2koFG81smzZl0IJ_Qik9NKexUiW1lq80layU_LfR85u049D0GEE8-PNvHmEvAC6Blq173A7rBkFtgbxiKyg41AKxurHZEXbri4FbeCUPE1pSynlTQNPyCljlWhpVa3I8DX4oMfgcSzQT06F_qbADTqfpmKH0fmgZosb450vork2MZlUaIy9Q11Yp2JILhVLE6dU_HLTUOghBu90xhdVi26co3lGTiyOyTw_1jPy49PH7xdfyqtvny8vPlyVmgs6lW3bWKY050YDFUzUive1bVibP5AfV0II2vYtUFSgVcMa3fTMql4w4DVWZ-T9QXc_q53ptfFTxFHuo8tubmRAJ__teDfITbiWVVXXjDVZ4M1RIIafs0mT3LmkzTiiN2FOEijUtOP5thl99R-6DXPMpu-oqmsZCMjU2wOl861SNPZ-GaBySVDmBOWSoASR6Zd_73_P_o4sA6-PACaNo43otUt_uLoT2cfCnR-4MO8fnHgL_VmxSg</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Haller, Steven T.</creator><creator>Kennedy, David J.</creator><creator>Shidyak, Amjad</creator><creator>Budny, George V.</creator><creator>Malhotra, Deepak</creator><creator>Fedorova, Olga V.</creator><creator>Shapiro, Joseph I.</creator><creator>Bagrov, Alexei Y.</creator><general>Oxford University Press</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><author>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure - physiology</topic><topic>Bufanolides - immunology</topic><topic>Bufanolides - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomegaly - etiology</topic><topic>Cardiomegaly - metabolism</topic><topic>Cardiomegaly - prevention & control</topic><topic>Comorbidity</topic><topic>Disease Models, Animal</topic><topic>Experimental diseases</topic><topic>Fibrosis</topic><topic>Immunoglobulin Fab Fragments - pharmacology</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Nephrectomy</topic><topic>Proto-Oncogene Protein c-fli-1 - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haller, Steven T.</creatorcontrib><creatorcontrib>Kennedy, David J.</creatorcontrib><creatorcontrib>Shidyak, Amjad</creatorcontrib><creatorcontrib>Budny, George V.</creatorcontrib><creatorcontrib>Malhotra, Deepak</creatorcontrib><creatorcontrib>Fedorova, Olga V.</creatorcontrib><creatorcontrib>Shapiro, Joseph I.</creatorcontrib><creatorcontrib>Bagrov, Alexei Y.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haller, Steven T.</au><au>Kennedy, David J.</au><au>Shidyak, Amjad</au><au>Budny, George V.</au><au>Malhotra, Deepak</au><au>Fedorova, Olga V.</au><au>Shapiro, Joseph I.</au><au>Bagrov, Alexei Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</atitle><jtitle>American journal of hypertension</jtitle><addtitle>Am J Hypertens</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>25</volume><issue>6</issue><spage>690</spage><epage>696</epage><pages>690-696</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><eissn>1879-1905</eissn><coden>AJHYE6</coden><abstract>Background
Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats.
Methods
In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery.
Results
In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced.
Conclusions
In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</abstract><cop>Basingstoke</cop><pub>Oxford University Press</pub><pmid>22378033</pmid><doi>10.1038/ajh.2012.17</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0895-7061 |
ispartof | American journal of hypertension, 2012-06, Vol.25 (6), p.690-696 |
issn | 0895-7061 1941-7225 1879-1905 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3355226 |
source | Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list) |
subjects | Animals Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Blood Pressure - drug effects Blood Pressure - physiology Bufanolides - immunology Bufanolides - metabolism Cardiology. Vascular system Cardiomegaly - etiology Cardiomegaly - metabolism Cardiomegaly - prevention & control Comorbidity Disease Models, Animal Experimental diseases Fibrosis Immunoglobulin Fab Fragments - pharmacology Immunoglobulin Fab Fragments - therapeutic use Kidney Failure, Chronic - complications Kidney Failure, Chronic - metabolism Kidney Failure, Chronic - surgery Male Medical sciences Myocardium - metabolism Myocardium - pathology Nephrectomy Proto-Oncogene Protein c-fli-1 - metabolism Rats Rats, Sprague-Dawley |
title | Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A10%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoclonal%20antibody%20against%20marinobufagenin%20reverses%20cardiac%20fibrosis%20in%20rats%20with%20chronic%20renal%20failure&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Haller,%20Steven%20T.&rft.date=2012-06-01&rft.volume=25&rft.issue=6&rft.spage=690&rft.epage=696&rft.pages=690-696&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1038/ajh.2012.17&rft_dat=%3Cproquest_pubme%3E1015094089%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1013982171&rft_id=info:pmid/22378033&rft_oup_id=10.1038/ajh.2012.17&rfr_iscdi=true |